Inosine pranobex in the treatment of viral dermatoses in children


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Acesso é pago ou somente para assinantes

Resumo

Many viral agents causing lesions of the skin and mucous membranes persist for a long time in the human body, causing secondary immunosuppression. Inosine pranobex with simultaneously immunomodulatory and antiviral activity, contributing to the active elimination of the virus from the body, is effective both in the treatment and prevention of various viral dermatoses. Numerous clinical studies, as well as the experience of the use of the drug in more than 70 countries around the world, indicate the efficacy and safety of inosine pranobex for the treatment of patients with confirmed viral infections.

Texto integral

Acesso é fechado

Sobre autores

Aleksandra Botkina

Pirogov Russian National Research Medical University

Email: botkina@gmail.com
Cand. Sci. (Med.), Associate Professor at the Department of Hospital Pediatrics n.a. Acad. V.A. Tabolin, Faculty of Pediatrics Moscow, Russia

M. Dubrovskaya

Pirogov Russian National Research Medical University

Moscow, Russia

O. Khandamirovan

Pirogov Russian National Research Medical University

Moscow, Russia

Bibliografia

  1. Исаков В.А., Архипов Г.С., Исаков Д.В. Патогенез и клинические особенности респираторных инфекций у часто болеющих пациентов. Материалы конференции. Великий Новгород, 2014. С. 92-100.
  2. Кускова Т.К., Белова Е.Г. Семейство герпес-вирусов на современном этапе. Лечащий врач. 2004;5:64-9.
  3. World Health Organization (WHO) (2004). Adolescent friendly health services: An agenda for change. Protecting young people from HIV and AIDS: The role of health services. Geneva: WHO. URL: http://www.who.int/whosis/whostat/2004/en/
  4. Игнатовский А.В. Герпетическая инфекция: диагностика, лечение. Врач. 2012;5:39-43.
  5. Looker K.J., Magaret A.S., May M.T., et al. Global and regional estimates of prevalent and incident Herpes simplex virus type 1 infections in 2012. PLoS One 2015;10(10):e0140765. doi: 10.1371/journal.pone.0140765.
  6. Pinninti S.G., Kimberlin D.W. Neonatal herpes simplex virus infections. Semin Perinatol. 2018;42(3):168-75. doi: 10.1053/j.semperi.2018.02.004.
  7. Осидак Л.В., Дриневский В.П., Цыбалова Л.М. и др. Острые респираторные инфекции у детей и подростков: практическое руководство для врачей. СПб., 2010.
  8. Федотов В.П., Рыбалкин С.Б., Романцов М.Г. Очерки по иммунокоррекции в дерматовенерологии. СПб., 2005.
  9. Xianzhi Jiang, Aziz Alami Chentoufi, Chinhui Hsiang, et al. The herpes simplex virus type 1 latency associated transcript (LAT) can protect neuronal derived C1300 and Neuro2A c ells from Granzyme B induced apoptosis and CD8 T-cell killing. J Virol. 2010;85:2325-32. doi: 10.1128/JVI.01791-10.
  10. Самгин М.А., Халдин А.А. Простой герпес (дерматологические аспекты). М., 2002, 160 с.
  11. Львов Н.Д. Герпесвирусы человека - системная, интегративная, лимфопролиферативная иммуноонкопатология. Русский медицинский журнал. 2012;22:1133-8.
  12. Bosch F.X., Broker T.R., Forman D., et al.Comprehensive control of human papillomavirus infections and related diseases. Vaccine. 2013;31(Suppl. 7):H1-31. Doi: 10.1016/j. vaccine.2013.10.003.
  13. Park I.U., Introcaso C., Dunne E.F Human Papillomavirus and Genital Warts: A Review of the Evidence for the 2015 Centers for Disease Control and Prevention Sexually Transmitted Diseases Treatment Guidelines. Clin Infect Dis. 2015;61(Suppl. 8):849-55. Doi: 10.1093/ cid/civ813.
  14. Dobson S., Deeks S., Money D. National Advisory Committee on Immunization (NACI). Statement on human papillomavirus vaccine. An advisory committee statement (ACS). Can Communt Dis Rep. 2007;33(ACS-2):1-31. PMID: 17520773.
  15. Moore R.A., Fornika D.J., Moravan V., et al. HPV type distribution in North America - apopulation-based study of 5000 British Columbia women. 23rd International Papillomavirus Conference & Clinical Workshop. Prague, September 1 to 7, 2006.
  16. Рахматулина М.Р., Кицак В.Я., Большенко Н.В. Современные методы профилактики развития онкологических заболеваний шейки матки у больных папилломавирусной инфекцией. Вестник дерматологии и венерологии. 2013;6:40-9.
  17. Кубанов А.А. Современные подходы к лечению папилломавирусной инфекции кожи и слизистых оболочек. Вестник дерматологии и венерологии. 2005;4:8-12.
  18. Tay S.K. Efficacy of inosine pranobex oral therapy in subclinical human papillomavirus infection of the vulva: a randomized double-blinded placebo controlled study.Int J STD AIDS. 1996;7(4):276-80. doi: 10.1258/0956462961917960.
  19. Beran J, Spajdel M., Katzerova V., et al. Inosine Pranobex Significantly decreased the case-fatality rate among PCR positive elderly with SARS-CoV-2 at three nursing homes in the Czech Republic. Pathogens. 2020;9(12):1055. Doi: 10.3390/ pathogens9121055.
  20. Bartovska Z., Andrle F, Beran O., Data from the first wave of Covid-19 from the Central Military Hospital, Prague, Czech Republic. Epidemiol Mikrobiol Imunol. 2020;69(4):164-71.
  21. Sliva J, Pantzartzi C.N., Votava M. Inosine Pranobex: a key player in the game against a wide range of viral infections and non-infectious diseases. Adv Ther. 2019;36:1878-905. doi: 10.1007/s12325-019-00995-6.
  22. You Y., Wang L., Li Y, et al. Multicenter randomized study of inosine pranobex versus acyclovir in the treatment of recurrent herpes la-bialis and recurrent herpes genitalis in Chinese patients. J Dermatol. 2015;42:596-601. doi: 10.1111/1346- 8138.12845.
  23. Lasek W., Janyst M., Wolny R., et al. Immunomodulatory effects of inosine pranobex on cytokine production by human lymphocytes. Acta Pharm. 2015;65(2):171-80. doi: 10.1515/acph-2015-0015.
  24. Petrova M., Jelev D., Ivanova A., Krastev Z. Isoprinosine Affects Serum Cytokine Levels in Healthy Adults. J Interf Cytokine Res. 2010;30:223-28. doi: 10.1089/jir.2009.0057.
  25. Milano S., Dieli M., Millott S., et al. Effect of isoprinosine on IL-2, IFN- gamma and IL-4 production in vivo and in vitro.Int J Immunopharmacol. 1991;13:1013-1018. doi: 10.1016/0192-0561(91)90055-c.
  26. Beran J., Salapova E,. Spajdel M., Isoprinosine Study (EWO ISO-2014/1) Team. Inosine pranobex is safe and effective for the treatment of subjects with confirmed acute respiratory viral infections: analysis and subgroup analysis from a Phase 4, randomised, placebo-controlled, double-blind study. BMC Infect Dis. 2016;16(1):648. doi: 10.1186/s12879-016-1965-5.
  27. Ahmed R.S., Newman A.S., O'Daly J., et al. Inosine acedoben dimepranol promotes an early and sustained increase in the natural killer cell component of circulating lymphocytes: a clinical trial supporting anti-viral indications.Int Immunopharmacol. 2017;42:108-14. doi: 10.1016/j.intimp.2016.11.023.
  28. Linhares R.E.C., Wigg M.D., Lagrota M.H.C., Nozawa C.M. The in vitro anti-viral activity of isoprinosine on simian rotavirus (SA-11) Braz J Med Biol Res. 1989;22:1095-103.
  29. You Y, Wang L., Li Y, et al. Multicenter randomized study of inosine pranobex versus acyclovir in the treatment of recurrent herpes labialis and recurrent herpes genitalis in Chinese patients. J Dermatol. 2015;42(6):596-601. doi: 10.1111/1346- 8138.12845.
  30. Majewska A., Lasek W., Janyst M., Mlynarczyk G. In vitro inhibition of HHV-1 replication by inosine pranobex and interferon-a. Acta Pol Pharm. 2016;73(3):637-44.
  31. Tobolska S., Terpilowska S., Jaroszewski J., Siwicki A.K. Genotoxicity and mutagenicity of inosine pranobex. J Vet Res. 2018;62(2):207-13. doi: 10.2478/jvetres-2018-0030.
  32. Исаков В.А., Исаков Д.В., Стуколкина Н.Е. Возможности терапии респираторных инфекций у часто болеющих пациентов. Клиническая фармакология и терапия. 2018;27(2):14-21.
  33. Janfckova O., Ancicova L., Briestenska K., Mistrikova J. The effect of Isoprinosine treatment on persistent infection of Balb/c mice infected with murine gammaherpesvirus 68. Acta Virol. 2017;61(1):32-8. doi: 10.4149/av_2017_01_32.
  34. Kumar R., Gupta N., Kodan P., et al. Battling COVID-19: Using old weapons for a new enemy Trop Dis Travel Med Vaccines. 2020;6:1-10. Doi: 10.1186/ s40794-020-00107-1.
  35. Караулов А.В. Иммуномодуляторы в профилактике и лечении респираторных инфекций у детей. Фарматека. 2012;1:10-3.
  36. Савенкова М.С., Балакирева Г.М., Румянцева И.Г Показания и опыт применения инозина пранобекса в педиатрической практике. Consilium Medicum (Педиатрия). 2017;4:52-5.

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies